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In the Chapel Hill colony of factor VIII-deficient dogs, abnormal
sequence (ch8, for canine hemophilia 8, GenBank no. AF361485)
follows exons 1–22 in the factor VIII transcript in place of exons
23–26. The canine hemophilia 8 locus (ch8) sequence was found in
a 140-kb normal dog genomic DNA bacterial artificial chromosome
(BAC) clone that was completely outside the factor VIII gene, but
not in BAC clones containing the factor VIII gene. The BAC clone
that contained ch8 also contained a homologue of F8A ( factor 8
associated) sequence, which participates in a common inversion
that causes severe hemophilia A in humans. Fluorescence in situ
hybridization analysis indicated that exons 1–26 normally proceed
sequentially from telomere to centromere at Xq28, and ch8 is
telomeric to the factor VIII gene. The appearance of an ‘‘upstream’’
genomic sequence element (ch8) at the end of the aberrant factor
VIII transcript suggested that an inversion of genomic DNA re-
placed factor VIII exons 22–26 with ch8. The F8A sequence ap-
peared also in overlapping normal BAC clones containing factor VIII
sequence. We hypothesized that homologous recombination be-
tween copies of canine F8A inside and outside the factor VIII gene
had occurred, as in human hemophilia A. High-resolution fluores-
cent in situ hybridization on hemophilia A dog DNA revealed a
pattern consistent with this inversion mechanism. We also identi-
fied a HindIII restriction fragment length polymorphism of F8A
fragments that distinguished hemophilia A, carrier, and normal
dogs’ DNA. The Chapel Hill hemophilia A dog colony therefore
replicates the factor VIII gene inversion commonly seen in humans
with severe hemophilia A.
Hemophilia A is a genetic bleeding disorder due to deficiencyof coagulation factor VIII and is characterized by sponta-
neous hemorrhage (particularly into joints) and excessive bleed-
ing after trauma or surgery. The clinical severity is inversely
proportional to the circulating factor VIII level in plasma, and
severe disease is associated with levels of factor VIII 1% of
normal (1). About 40% of severe human hemophilia A is
associated with recombination between a transcribed DNA
sequence within intron 22 of the factor VIII gene and nontran-
scribed copies of homologous sequences that are telomeric to the
factor VIII gene on Xq28 (2–6). The remaining cases are caused
by hundreds of distinct point mutations, deletions, or insertions
(7). Several experimental animal models of hemophilia A (spon-
taneous and artificially induced knockouts) have been charac-
terized with regard to their phenotype and underlying genetic
defect (8–11). The hemophilia A dog colony at the University of
North Carolina at Chapel Hill was founded in 1947 from a
purebred male Irish Setter with severe hemophilia A (8). The
colony has been an important model for studies of hemostasis
and preclinical testing of therapeutic factor VIII concentrates
(12–15). Although the gene defects responsible for canine
hemophilia B (coagulation factor IX deficiency) have been
elucidated in at least two spontaneous hemophilia B dog colo-
nies (16, 17), the molecular mechanism for spontaneous hemo-
philia A in animals has remained unknown. During analysis of
the Chapel Hill hemophilia A dog colony, we discovered an
abnormal transcript in which the normal canine factor VIII
sequence changes to a novel sequence (designated ch8 for canine
hemophilia 8: GenBank no. AF361485) immediately following
exon 22. This finding suggested a mutation that permitted
splicing of ch8 into the factor VIII transcript but did not indicate
the mechanism for the mutation. In this report, we present
evidence for an inversion in the Chapel Hill hemophilia A dog
colony that is analogous to the common inversion seen in
humans, indicating a recurring mechanism for hemophilia A due
to instability of genomic DNA in the factor VIII gene in different
species.
Materials and Methods
Chapel Hill Hemophilia A Dogs. Experiments were approved by the
University of North Carolina at Chapel Hill Institutional
Animal Care and Use Committee. Hemizygous males and
homozygous females from the Chapel Hill hemophilia A
colony lack coagulation factor VIII activity, demonstrate
prolonged in vitro laboratory clotting parameters, and exhibit
a severe hemophilia A bleeding phenotype.
RACE. Total RNA was prepared from euthanized hemophilia A
dog liver or spleen by extraction with Trizol (Life Sciences,
Bethesda, MD) and used to make polyA RNA with the Poly-
Attract mRNA isolation kit (Promega, Madison, WI). RACE
(5 and 3) was performed by using the CLONTECH SMART
RACE kit (CLONTECH). Gene-specific primers were de-
signed by using published normal canine factor VIII sequence
(18). Synthetic primers were incorporated into the initial first-
and second-strand DNA synthesis steps, and nested primers
were also used in subsequent amplification steps. Initial PCR
was performed by using a Perkin–Elmer 480 PCR cycler and
‘‘touchdown’’ PCR conditions described for the CLONTECH
SMART RACE kit. Nested PCR was performed by using a
Perkin–Elmer 2400 cycler. See Fig. 5, which is published as
supporting information on the PNAS web site, www.pnas.org,
for PCR amplification strategy.
TA Cloning of PCR Fragments. PCR fragments were cloned into
pCR3.1 (Invitrogen) and sequenced with universal and/or
gene-specific primers from normal canine factor VIII and ch8
sequence.
DNA Sequence Determination and Analysis. PCR products were
sequenced by Bioserve (Laurel, MD). Analysis of sequence
data was performed with DNASTAR (DNAstar, Madison, WI)
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by using the sequence editing, mapping, comparison, and
assembly modules. Comparison of canine factor VIII, ch8, and
factor 8-associated locus (F8A) sequence with GenBank sub-
missions was performed with the Entrez Genomes BLASTN/
BLASTP programs (19).
Bacterial Artificial Chromosome (BAC) Library Screening. The
RPCI-81 BAC library (Children’s Hospital of Oakland Re-
search Institute, Oakland, CA), which contains normal male
Doberman Pinscher genomic DNA, was screened with 32P-
labeled DNA probes from normal canine factor VIII exon 14,
exon 22, or ch8 from the abnormal hemophilia A transcript.
The exon 14 probe was prepared from the 1.2-kb EcoRI digest
fragment from the pCR3.1 TA clone containing part of the
B-domain amplified by using reverse transcription–PCR. The
170-bp exon 22 probe was obtained by PCR amplification of
exon 22 from normal genomic DNA with exon 22 primers. The
ch8 probe was obtained by digestion of the TA clone contain-
ing the exon 22/ch8 fusion fragment with RcaI and EcoO109I
restriction enzymes (Fig. 1) and gel purification of the 423-bp
fragment. Positive clones identified by autoradiography of
robotically spotted filters were grown in chloramphenicol–LB
medium and BAC DNA purified after alkaline lysis and
ultracentrifugation in cesium chloride/trif luoroacetic acid
(Amersham Pharmacia Biotech). DNA for f luorescent in situ
hybridization was prepared in the absence of ethidium bro-
mide. BAC clones were analyzed for the presence of canine
factor VIII exons 2, 14, 22, 23, 23–25, and 26 by PCR by using
the TaKaRa LA PCR kit, Ver. 2.1 (Intergen, Purchase, NY)
and the primers from the canine factor VIII gene (all primer
sequences available on request).
Fluorescence in Situ Hybridization (FISH) Analysis of Normal and
Hemophilia A Dog Chromosomes/DNA Fibers. Metaphase spreads
were prepared by standard air-drying methods as described
previously (20) by using peripheral blood leukocytes or skin
fibroblasts. DNA fibers were obtained by lysis of cells in 2 M
MgCl2/25 mM TrisHCl/1%Triton X-100 for 30 min at room
temperature, followed by air drying on slides in an upright
position for 5 min. Slides were fixed in methanol/acetic acid
(3:1) for 20 min. FISH of metaphases and fibers was performed
with Spectrum orange, Spectrum green (Vysis, Downers
Grove, IL), and Cy5- (Life Science, Boston) labeled DNA by
nick translation (20). On each slide, 200 ng of each labeled
DNA probe was applied. Repetitive sequences were blocked
with normal canine genomic DNA. Ten microliters of a
hybridization mixture containing the labeled DNA in 50%
formamide, 2 SSC, and 10% dextran sulfate (pH 7.0) were
denatured at 75°C for 10 min, then incubated at 37°C for 30
min for preannealing. Slides containing chromosomes or DNA
fibers were incubated for at least 1 h at 37°C in 2 SSC and
dehydrated in a series of 70, 80, and 90% ethanol solutions for
2 min each. Slides were then denatured in 70% formamide/2
SSC for 2 min and sequentially in 70, 80, 90, and 100% ethanol
at 20°C before hybridization. Posthybridization washes were
performed at 45°C sequentially in 50% formamide, 2 SSC for
15 min, then 0.1  SSC for 10 min. Slides were counterstained
with 250 ng/l 4,6-diamidino-2-phenylindole-antifade (Vec-
tor, Burlingame, CA).
Southern Blot Analysis of Genomic and BAC DNA. Genomic DNA
(10–20 g) was digested overnight with various restriction
enzymes and subjected to 0.7% agarose gel electrophoresis.
After UV photography, the gel was soaked for 30 min in
denaturing solution, then subjected to downward capillary
transfer of DNA fragments onto BrightStar-Plus nylon mem-
brane per the manufacturer’s directions (Ambion, Austin,
TX). After UV crosslinking, the membrane was prehybridized
in Hybrisol II (Intergen) at 68° for at least 1 h, then the
Fig. 1. Chapel Hill canine factor VIII exon 22/ch8 junction. In the Chapel Hill hemophilia A canine factor VIII transcript, the novel sequence ch8 follows
exon 22. The predicted amino acid sequence is shown in three-letter code below the nucleic acid sequence data. The ORF of exon 22 continues 22 amino
acids after canine factor VIII Met 2116 before the first of several stop codons (depicted as periods) in ch8. Sites of cleavage by various restriction sites used
to characterize the genomic DNA or generate DNA probes are shown above the DNA sequence. pA, the polyadenylation signal sequence, AATAAA.
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appropriate 32P-labeled probe was added, and hybridization
was performed overnight at 68°. The membrane was subse-
quently washed twice in 2  SSC at 45°, once in 0.5 
SSC/0.4% SDS at 55°, and once in 0.5  SSC/0.4% SDS at 68°
before autoradiography at –80°. BAC clone DNA was analyzed
similarly by using 30–300 ng of DNA for the restriction digest.
Results
Determination of cDNA Sequence in Chapel Hill Hemophilia A Dog.
Seven thousand fifty-five nucleotides of factor VIII cDNA
sequence were elucidated from analysis of RACE PCR frag-
ments derived from spleen and/or liver mRNA. Normal canine
factor VIII sequence starting 187 nucleotides 5 to the ATG
start site proceeded through exon 22. The sequence was in
complete agreement with normal canine factor VIII sequence
(18), including all arginine cleavage sites for protein C and S
and all tyrosines predicted to be phosphorylated after trans-
lation. The 5 sequence upstream of published normal canine
factor VIII sequence was in agreement with unpublished
normal canine factor VIII data (Christine Hough, personal
communication). Immediately after exon 22, there was a novel
sequence, ch8, which diverged from the normal canine factor
VIII cDNA (Fig. 1). Four hundred twenty-one nucleotides
after the exon 22/ch8 junction, there was a polyadenylation
signal sequence (AATAAA) followed by a polyA tail. This
abnormal transcript was consistently amplified with various
primer combinations anchored at the 5 end by canine factor
VIII-specific oligonucleotides and at the 3 end by either the
CLONTECH nested universal primer for the 3 RACE reac-
tion or by a primer specific to ch8 sequence. Northern blot
analysis of the factor VIII transcript was unsuccessful in both
normal and hemophilia A dogs because of the extremely low
abundance of the factor VIII transcript.
Analysis of the Novel Fusion Transcript Sequence. A search of all
known nucleic acid sequence data for homology with the 421
bp of ch8 sequence was performed with the BLASTN, Ver. 2.1.2,
program (19). The search revealed homology with human BAC
clone RP13–228I21 (GenBank accession no. AL356738) that is
found telomeric to the human factor VIII gene on the X
chromosome (data not shown). A direct comparison of ch8
with the human factor VIII-associated gene (F8A) that is
involved in the common inversion that causes severe hemo-
philia A in humans (2–6) revealed no similarity. The normal
canine factor VIII ORF ends 21 amino acids after Met 2116 of
the C1 domain of factor VIII. After the first stop codon, all
other reading frames in register with the factor VIII reading
frame are 25 aa in length. Analysis of all potential ch8 ORFs
revealed no significant homology to any known protein se-
quence by using the BLASTP program (19).
Exon 22 and ch8 Are Not Contiguous in Hemophilia A Genomic DNA.
Southern blot analysis showed no difference in length between
hemophilia A and normal canine DNA fragments that hybrid-
ized with the ch8 probe after digestion with BanII, RcaI, AflIII,
and BglI, or EcoO109I and BglI. Furthermore, exon 22 and ch8
were not contiguous in normal and hemophilia A dog genomic
DNA, because the fragments were larger than predicted if
exon 22 were contiguous with ch8 in genomic DNA (see Fig.
6, which is published as supporting information on the PNAS
web site).
Exons 23–26 Are Intact in Hemophilia A Dog Genomic DNA. Exons
23–25 were amplified from normal or hemophilia A dog DNA
as a single PCR product. Likewise, exon 26 (which is separated
from exons 23–25 by a large intron) could be amplified
separately as a 209-bp PCR product (see Fig. 7, which is
published as supporting information on the PNAS web site).
All amplified PCR products from normal and hemophilia A
dogs were subjected to sequence analysis, and hemophilia A
and normal dog factor VIII sequences were identical for all
PCR products.
ch8 Hybridizes to Dog Chromosome Xq28. BAC clones that con-
tained either ch8 (291 M9) or factor VIII exons 1–22 (292 C4)
were isolated from the normal male canine genomic DNA
BAC library RPCI-81 and used in FISH analysis of normal and
hemophilia A dogs. Two-color FISH analysis of metaphase
spreads from hemophilia A, and normal dog lymphocytes
showed localization of factor VIII exons 1–22 to Xq28 as
expected in normal and hemophilia A metaphases (20). The
ch8 probe localizes to Xq28 in a position immediately telo-
meric to exons 1–22 in both hemophilia A and normal met-
aphases (Fig. 2).
Evidence for an Inversion in Hemophilia A Dogs from FISH Analysis of
Individual DNA Fibers. Analysis of individual DNA fibers from
normal and hemophilia A dog fibroblasts, with the normal
BAC probe containing ch8 and F8A (291 M9) and two
overlapping probes (292 C4 and 314 O16) representing por-
tions of dog factor VIII, is shown in Fig. 3. BAC probe 291 M9
is approximately 140 kb in length, and shotgun sequence
analysis shows that it contains the novel sequence ch8 as well
as F8A but contains no factor VIII sequence (see Fig. 8, which
is published as supporting information on the PNAS web site).
It was shown by two-color FISH analysis of normal dog
metaphase chromosomes (Fig. 2 and Fig. 9, which is published
as supporting information on the PNAS web site) to lie in a
position telomeric to 292 C4 (which contains factor VIII exons
1–22 of the dog factor VIII gene). In other analyses, we also
demonstrated that 291 M9 localized to a position telomeric to
probe 314 O16, which contained factor VIII exons 22–26 (Fig.
3 and metaphase FISH data not shown). Thus, the normal dog
DNA fiber FISH analysis with these three probes shown in Fig.
3 indicated that 291 M9 is extragenic to and separate from the
factor VIII gene, whose direction of transcription must pro-
ceed from exons 1–22 (292 C4) toward exons 23–26 (314 O16).
The appearance of ch8 at the 3 end of the hemophilia A factor
VIII transcript (despite its position upstream to factor VIII in
genomic DNA) makes sense only in the context of an inversion
of genomic DNA. Fiber FISH analysis of hemophilia A dog
DNA reveals that the extragenic 291 M9 probe signal has been
split, and factor VIII sequence (292 C4) has been brought next
to the 291 M9 signal where a gap existed in normal dog DNA
(Fig. 3). These data confirmed an inversion of genomic DNA
in the Chapel Hill hemophilia A dogs.
BAC Clones 291 M9, 292 C4, and 314 O16 Contain F8A Sequence. F8A
sequence was amplified from the three normal dog DNA BAC
clones 291 M9, 292 C4, and 314 O16 by PCR (see Fig. 10, which
is published as supporting information on the PNAS web site).
All three F8A PCR product sequences were identical. Hence,
identical F8A sequence is found within the normal dog factor
VIII gene (in clones 292 C4 and 314 O16) and outside the
factor VIII gene (in clone 291 M9).
A HindIII Restriction Fragment Length Polymorphism (RFLP) of F8A
Sequence That Differs Among Hemophilia A, Carrier, and Normal Dog
Genomic DNA. We predicted that a factor VIII gene rearrange-
ment involving multiple genomic copies of the canine F8A
sequences would result in an RFLP that could distinguish
hemophilia A, carrier, and normal dogs’ genomic DNA. Fig. 4
shows a Southern blot of dog genomic DNA digested with
HindIII and probed with canine F8A. There were 28- and 13-kb
fragments present in normal dog genomic DNA that were
replaced by two bands of 21 and 23 kb in the hemophilia A dog.






As expected in an X-linked disease, the carrier female had
bands from both the normal and hemophilia A patterns.
Additional HindIII fragments of equal intensity could be
seen in normal, carrier, and hemophilia A dog genomic DNA
at molecular weights of 3.5 and 5 kb (see Fig. 11, which is
published as supporting information on the PNAS web site),
suggesting additional copies of F8A not involved in the he-
mophilia A gene rearrangement exist (as is true in humans).
The smaller of these two HindIII fragments corresponded to
a discrete band seen by ethidium bromide staining after
electrophoresis of digested DNA and may represent nonspe-
cific binding to a particularly abundant HindIII fragment in
genomic DNA. BACS 291 M9, 292 C4, and 314 O16 were also
digested with HindIII and probed with canine F8A after
electrophoresis. In 291 M9 (the extragenic clone) a 28-kb band
was seen, whereas BAC clones 292 C4 and 314 O16 (which
overlap in the factor VIII gene) both contained the 13-kb band
seen in normal dog genomic DNA (Fig. 4).
Discussion
The Hemophilia A Inversion in Dogs Recapitulates the Human Inver-
sion. A novel sequence, ch8, replaces the last four exons of the
normal factor VIII transcript from Chapel Hill hemophilia A
dogs. The last four exons of the factor VIII are not deleted
from genomic DNA. Isolation of a normal BAC clone con-
taining ch8 permitted sequence and cytogenetic analysis of this
region. Large-scale sequence analysis of this BAC (AF523316)
revealed no factor VIII sequences, but FISH analysis of normal
and hemophilia A dogs showed that ch8 and a copy of F8A are
located together near the factor VIII gene on the X chromo-
some. This finding focused our attention on the Xq28 region.
We sought and found in the BAC clone containing ch8 an 87%
identical canine homologue of F8A (see Fig. 12, which is
published as supporting information on the PNAS web site).
We also found copies of this sequence in overlapping BAC
clones that contained the factor VIII gene. FISH analysis of
normal dog metaphase chromosomes and DNA fibers, by using
the ch8 BAC clone and the two factor VIII BAC clones,
Fig. 2. Metaphase FISH Analysis of hemophilia A and normal dogs with
ch8 and factor VIII BAC clone probes. FISH of normal and hemophilia A dog
chromosomes with BAC clones specific for canine factor VIII exons 1–22 (292
C4) or the novel ch8 sequence (291 M9) localizes both sequences to Xq28.
292 C4 (containing canine factor VIII exons 1–22) is red and 291 M9
(containing the novel ch8 sequence) is green.
Fig. 3. DNA fiber FISH analysis of hemophilia A and normal dogs with ch8
and factor VIII BAC clone probes. FISH of normal and hemophilia A dog
genomic DNA with factor VIII and related BAC probes is shown. BAC clone
291 M9 (which is outside of the factor VIII gene and contains both ch8 (the
3 end of the abnormal hemophilia A factor VIII transcript) and F8A (the
factor VIII-associated gene sequence) is green. BAC clone 292 C4 (which
contains factor VIII exons 1–22 as well as a copy of F8A) is blue. BAC clone
314 016, which contains factor VIII exons 23–26 and one copy of F8A, is red.
BAC clones 292 C4 and 314 O16 presumably overlap in the vicinity of intron
22. BAC clones 292 C4 and 314 O16 establish the orientation of factor VIII
exons 1–22 and 23–26. Rearrangement of DNA is evident from inversion of
part of the 291 M9 probe with part of that for 292 C4 as well as the shift in
the normal gap between extragenic probe 291 M9 and factor VIII probes
292 C4 and 314 O16.
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revealed the order of sequences on the long arm of the X
chromosome to be: telomere 3ch83 factor VIII exons 1–22,
factor VIII exons 23–26,3 centromere. The presence at the 3
end of the hemophilia A factor VIII transcript of a sequence
normally found in genomic DNA at a position 5 (‘‘upstream’’)
of the factor VIII gene indicated an inversion of DNA. We
have shown direct evidence of an inversion by FISH analysis
of hemophilia A dog DNA fibers (Fig. 3). Finally, we have
found a HindIII RFLP involving F8A-containing DNA frag-
ments that discriminated among normal, hemophilia A, and
carrier females in the Chapel Hill dog colony (Fig. 4).
The Abnormal Factor VIII Transcript Occurs in Different Hemophilia
A Dog Colonies. The canine X-chromosome in this region is
shown to be syntenic with the human factor VIII locus at Xq28
(20). Independent cases of abnormal mRNA splicing after
exon 22 in dogs and humans suggest that this is an intrinsically
unstable region of DNA across species. Other investigators
have found a nearly identical transcript in a different hemo-
philia A dog colony at Queen’s University, Ontario (21). The
independent origin of the Queen’s University colony (in 1980)
from the Chapel Hill dog colony (in 1947) is assured by the
separate time and place of origin, as well as the different
purebred dog strains (miniature schnauzer and Irish Setter,
respectively) in which they appeared (8–10). The transcript
from the Queen’s University colony also differs from the
Chapel Hill colony at five polymorphic sites in the normal
coding sequence in exons 1–22, after which the same aberrant
sequence is encountered in each (21). Finding the same
abnormal transcript in separate spontaneous hemophilia A
dog colonies was also reminiscent of the common F8A-
mediated, factor VIII intron 22 inversions in separate de novo
cases of severe hemophilia A in humans (2–6). Southern blot
analysis of KpnI-digested Chapel Hill hemophilia A dog DNA
by using an F8A probe shows a pattern similar to that shown
in the Queen’s University colony (data not shown). These
findings predict that inversions involving the factor VIII gene
should occur spontaneously in other animal species that have
duplicated F8A sequence in and near the factor VIII gene. In
this regard, it is notable that no spontaneous factor VIII
mutation or inversion has been observed in mice, which lack
the multiple copies of F8A that would be required for homol-
ogous recombination but do have a single extragenic copy of
F8A (22).
Role of ch8 and F8A. Because we were unable to find any RFLP
that distinguished normal and hemophilia or carrier dog
genomic DNA by using ch8 sequence as a probe (Fig. 6 and
other data not shown), it seems likely that ch8 is not at the
immediate site of recombination but is the best alternative
sequence for splicing near the rearranged factor VIII gene.
Part of the ch8 sequence bears modest homology to human
X-chromosome working draft sequence (with which it is
syntenic); however, its role is not obvious. The relatively short
potential ORFs that are implied by this sequence just before
the polyadenylation signal (Fig. 1) suggest that it does not
encode a functional protein and may reside in an untranslated
portion of another gene. There is modest homology between
ch8 and various repetitive DNA elements, particularly short,
interspersed, nuclear elements that are found throughout most
eukaryotic genomes, including the dog (23–26).
The function of F8A (which is ubiquitously expressed in
mammalian tissues) is unclear at this time, although it may
have a role in localization of the huntingtin gene product to the
cell nucleus (27). The multiple canine F8A bands on the
Southern blot of genomic DNA and normal dog BAC DNA
suggest that two copies are involved in the recombination and
at least one more copy that is not involved in the hemophilia
A inversion (Figs. 4 and 11). This is analogous to the common
human factor VIII inversion mediated by F8A.
The Chapel Hill Hemophilia A Dog as a Model for Preclinical Testing
of Novel Hemophilia A Therapies. The Chapel Hill hemophilia A
dogs have been useful for preclinical testing of human factor
VIII concentrates, because they have a severe bleeding phe-
notype and no activity or antigen to interfere with measure-
ments of factor VIII levels. These features are also useful for
the testing of factor VIII gene transfer vectors that might be
used for gene therapy of hemophilia A. Most current ap-
proaches contemplate replacement of factor VIII by expres-
sion of factor VIII after transduction of various tissues with a
gene transfer vector. The finding of a gene inversion in the
Chapel Hill hemophilia A dog colony similar to the human
hemophilia A inversion suggests a strategy whereby the miss-
ing exons could be replaced by transsplicing of mRNA. Trans-
splicing of mRNA takes advantage of the capacity of certain
group I or II intron RNA sequences to catalyze splicing of one
mRNA with another (28–30). This strategy has been used in
vitro to repair sickle  globin mRNA in erythrocytes (31). In
principle, this approach should be applicable to human hemo-
philia A and testable in hemophilia A dogs. Notably, the
Chapel Hill hemophilia A dogs would require the replacement
of only the final 627 nucleotides of the transcript (exons 23–26)
for correction. Furthermore, the exon 22 sequence proximal to
the inversion site is identical in humans and dogs. Thus,
potentially useful mRNA transsplicing constructs for humans
with the common factor VIII inversion could be tested in the
Chapel Hill hemophilia A dogs with the same mutation and
identical exon 22 target sequence.
We dedicate this manuscript to the memory of a pioneer in blood
coagulation research, the late Dr. Kenneth M. Brinkhous, who initially
identified the Chapel Hill strain of hemophilia A dogs and used them for
Fig. 4. A HindIII RFLP of F8A fragments distinguishes hemophilia A, carrier
female, and normal dog genomic DNA. The 28- and 13-kb HindIII bands
found in normal dog genomic DNA (N) are not found in hemophilia A dog
DNA (H), which demonstrates bands at 21 and 23 kb. The carrier female (C)
has all four bands seen in hemophilia A or normal dog DNA. The normal dog
BAC clone 291 M9 has the 28-kb band, suggesting the 28-kb fragment is
extragenic to factor VIII. Normal dog BAC clones 292 C4 and 314 O16
contain the 13-kb band, suggesting the 13-kb fragment is within factor VIII,
presumably in intron 22 where these BACs overlap. Not shown are bands
at 5 and 3.5 kb that are present in all three genomic DNA samples (see
Fig. 11).






over 50 years to improve the lives of human hemophilia A patients. We
thank Ms. Robin Raymer for outstanding management and care of the
hemophilic dogs at the Francis Owen Blood Research Laboratory at
University of North Carolina, Chapel Hill, and Jeff Touchman of the
National Institutes of Health Intramural Sequencing Core facility for
help with sequence analysis of BAC 291 M9 and deposition of sequence
data in GenBank. This work was supported in part by National Institutes
of Health Grant HL63098.
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